All In Biotech

Drug Trial Radar · NCT06238687

A Study of STRO-002 in Chinese Adults With Epithelial Ovarian Cancer and Other Advanced Malignant Solid Tumors

A Phase I/IIa Study to Evaluate the Safety, Tolerability , Pharmacokinetics and Preliminary Efficacy of STRO-002 in Chinese Adults With Advanced Epithelial Ovarian Cancer, Endometrial Cancer, and Other Advanced Malignant Solid Tumors.

Last checked: Nov 19, 2026Latest source record: Apr 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

19

Actual

Start

Nov 8, 2023

Primary completion

Jun 6, 2025

Study completion Dec 30, 2025

Sponsor

Sponsor type
Industry
Collaborators
Sutro Biopharma, Inc.
First posted
Feb 2, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multi-center, open-label, monotherapy dose escalation, PK bridging, and dose expansion Phase I/IIa study in Chinese adult subjects to evaluate the safety, tolerability, Pharmacokinetics (PK) profiles, immunogenicity, and preliminary efficacy of STRO-002 in patients with advanced malignant solid tumors.

Conditions

  • Neoplasm Malignant

Interventions

  • STRO-002Biological

    STRO-002 is an Antibody-drug conjugates (ADCs) combine the specificity of monoclonal antibodies with the anti-tumor activity of cytotoxic drugs.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. DLT AssessmentTime frame: From Day1 to Day21 after first dose of STRO-002
  2. AE AssessmentTime frame: From first dose of STRO-002 until 28 days after the last dose of STRO-002
  3. AUCTime frame: From first dose of STRO-002 until 28 days after the last dose of STRO-002.
  4. CmaxTime frame: From first dose of STRO-002 until 28 days after the last dose of STRO-002.
  5. Half life (t1/2)Time frame: From first dose of STRO-002 until 28 days after the last dose of STRO-002.
  6. Overall response rate (ORR)Time frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 24 months
  7. Determine the recommended phase II dose (RP2D)Time frame: From first dose of STRO-002 until 28 days after the last dose of STRO-002.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • West China Hospital of Sichuan University

    Chengdu, Sichuan, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.